Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Santen Offloads Entire North American Portfolio to Visiox, Harrow
July 20, 2023
- Kissei Pulls Japan NDA for Spinocerebellar Degeneration Treatment
July 20, 2023
- Remitch OD Tablets Approved in Thailand: Toray/Meiji Pharma
July 20, 2023
- More Crestor Generics Now on Equal Footing with Originator
July 20, 2023
- Anthony Mallet Tapped as Servier Japan Chief
July 19, 2023
- Astellas Becomes 1st Japan Pharma to Sue US Govt over IRA
July 19, 2023
- Roche Group Sues Biogen over Actemra Biosimilar
July 18, 2023
- Meiji’s Stelara Biosimilar Accepted for EU Review
July 18, 2023
- Zolbetuximab Accepted for EMA Review in CLDN18.2 Gastric Cancer: Astellas
July 18, 2023
- Nichi-Iko to Discontinue 258 Products, Largest Number Yet
July 14, 2023
- Gilead Japan Building Sales Force to Prep for Full Oncology Entry: Chief
July 14, 2023
- Enhertu Adds HER2 Low Breast Cancer Nod in China
July 14, 2023
- Daiichi Sankyo Espha Rolls Out Follow-On AG for Maintate
July 13, 2023
- Organon to Succeed Bepricor Distribution from Daiichi Sankyo in Japan
July 13, 2023
- Astellas’ Iveric Bio Acquisition Completed
July 13, 2023
- Generic Makers, Industry, and Govt Must Join Hands to Build Long-Term Stable Supply System: Towa Chief
July 13, 2023
- Meiji to Develop Lineup Unaffected by Price Revisions, Bolster Earnings from New Drugs/Generics in Focus Areas
July 12, 2023
- SanBio to Ax 22 Jobs in US, Focus on Work towards Japan Cell Therapy Launch
July 12, 2023
- RaQualia’s Acid Reducer Tegoprazan Launched in Indonesia
July 12, 2023
- JCR Grabs German OK for Launch of Global PI/II for MPS IIIA Drug
July 12, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…